布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病的效果和安全性分析 - 论文 

?临床研究?中国当代医药2019年5月第26卷第15期布地奈德福莫特罗联合嗟托滉钱治疗慢性阻塞性

肺疾病的效果和安全性分析曾立胜广东省惠州市惠城区小金口人民医院医务科，广东惠州516023|摘要］目的探讨布地奈德福莫特罗联合嗟托漠镀治疗慢性阻塞性肺疾病(COPD)的效果和安全性。方法选取

2017年4月-2018年4月我院收治的117例COPD患者作为研究对象,采用随机数字表法将其分为参照组(n= 59)和实验组(“=58)。参照组采用布地奈德福莫特罗吸入剂治疗，实验组则采用布地奈德福莫特罗吸入剂和嗟托

漠镀干粉胶囊联合治疗。观察两组在治疗前后的1 s用力呼气容积(FEVJ、ls用力呼气容积/用力￠15活量比值 (FEVi/FVO.FEV,预计百分比(FEV%)以及最大呼气流速(PEF)的改善情况，并观察临床症状改善情况和分析

不良反应发生情况。结果治疗前，两组的FEV1SFEV,/FVC.FEV,%以及PEF等肺功能指标比较，差异无统计学意 义(P>0.05)o治疗后，两组的各项肺功能指标均有不同程度的提高(P<0.05),且实验组的各项肺功能指标高于参 照组，差异有统计学意义(P<0.05)。两组治疗前的圣乔治呼吸问卷(SGRQ)评分比较，差异无统计学意义(P> 0.05)o治疗后实验组的SGRQ评分低于参照组，差异有统计学意义(P<0.05)o实验组和参照组治疗的不良反应总

发生率分别为15.52%、11.86%,差异无统计学意义(60.05)。结论布地奈德福莫特罗联合嗟托澳镀治疗COPD,

能提高临床效果，有效改善患者的肺功能指标,且安全性良好，值得临床推广。［关键词］慢性阻塞性肺疾病；布地奈德福莫特罗；噬托渙鮫;肺功能［中图分类号］R563.9 ［文献标识码］A ［文章编号］1674-4721(2019)5(0)-0078-03Effect and safety of Budesonide Formoterol combined with TiotropiumBromide in the treatment of chronic obstructive pulmonary diseaseZENG Li-shengDepartment of Medical, Xiaojinkou People, s Hospital of Huicheng District in Huizhou City, Guangdong Province,Huizhou 516023, China[Abstract] Objective To investigate the effect and safety of Budesonide Formoterol combined with Tiotropium Bromide

in the treatment of chronic obstructive pulmonary disease (COPD). Methods A total of 117 patients with COPD admit-

ted in our hospital from April 2017 to April 2018 were selected as study objects. They were divided into control group (n=59) and experimental group (n=58) according to random number table method. The patients in the control group were treated with Budesonide Formoterol Inhalation, the patients in the experimental group were treated with Budes-

onide Formoterol Inhalation and Tiotropium Bromide Dry Powder Capsules. The improvement of forced expiratory vol-

ume (FEV]), forced expiratory volume/forced vital capacity ratio (FEV/FVC), predicted percentage of FEV\\ (FEV}%)

and maximal expiratory flow (PEF) were observed before and after treatment. And the improvement of clinical symptoms and the adverse reactions were observed. Results There was no significant difference in FEVFEV(/FVC, FEV)% andPEF between the two groups before treatment (P>0.05). After treatment, the pulmonary function indexes of the two groups were improved to some extent (P<0.05), and the pulmonary function indexes of the experimental group were higher than

those of the control group (P<0.05). There was no significant difference in (SGRQ) score of St George's respiratory

questionnaire between the two groups before treatment (P>0.05). The SGRQ score of the experimental group was signifi-cantly lower than that of the control group (P<0.05). The total incidence of adverse reactions in the experimental group

and the control group were 15.52 and 11.86, respectively. There was no significant difference between the two groups(P>0.05). Conclusion Budesonide Formoterol combined with Tiotropium Bromide in the treatment of COPD, can im-

prove the clinical effect, improve the pulmonary function more effectively, and is safe and worthy of clinical promotion.[Key words] Chronic obstructive pulmonary disease;

［作者简介］曾立胜(1974-),男，汉族，广东惠州人，主治医

Budesonide Formoterol; Tiotropium Bromide; Pulmonary function师，主要从事内科疾病研究78 CHINA MODERN MEDICINE Vol. 26 No. 15 May 2019